The Case for Less Expensive Biotech Drugs

While drug makers and consumer groups lobby Congress and the Obama administration on the best way to bring cheaper versions of biotech drugs to market, a U.S. company is already doing so overseas. How does this work and what are the prospects for biogenerics in the U.S. Dr. Sumant Ramachandra, Chief Scientific Officer at Hospira Inc. tells host Bruce Japsen about the company's work bringing cheaper biotech drugs to market.